Stocks Health care AEON
NYSE · Health careAEON Biopharma, Inc. (AEON)
It posted a net loss of $54.6M. In fiscal 2025 capital spending exceeded operating cash flow by $17.3M. At June 30, 2026 it held $3.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about AEON Biopharma, Inc.
- Net worth
- AEON Biopharma, Inc. has a market value (market cap) of $8.8M at the latest share price, and shareholders' equity of -$15.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $17.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- AEON Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What AEON Biopharma, Inc. does
AEON Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker AEON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$39.2M | -$3.95 | -$17.3M |
| 2024 | n/a | $42M | $72.93 | n/a |
| 2022 | n/a | -$52.6M | -$0.38 | -$35.9M |
| 2021 | n/a | $8.2M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What AEON Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026
- August 21, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- August 3, 2026
- July 23, 2026Other event 8-K
- July 21, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
- July 13, 2026Form S-1MEF filing S-1MEF
- July 9, 2026
Insider trades
What the people running AEON Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $243.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Lynch Timothy P10% owner | Bought | 1,150,000 | $243.5K |
| June 17, 2026 | Carter Eric GDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Fischer JostDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Forth MarcDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Palmisano Robert JDirector | Received as pay | 222,684 | - |
| June 17, 2026 | Thunen Shelley BDirector | Received as pay | 222,684 | - |
| April 2, 2026 | Bencich JohnCHIEF FINANCIAL OFFICER | Received as pay | 754,717 | - |
| March 4, 2026 | Oh ChadCHIEF MEDICAL OFFICER | Received as pay | 1,316,872 | - |
Who owns AEON
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Daewoong Co.,Ltd. ("DWC")13D, may seek influence with 1 related filers | 49.99% | January 29, 2026 |
| Timothy P. Lynch13G, passive | 13% | August 21, 2026 |
| Chernett Jorey13G, passive | 9.9% | May 30, 2025 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.9% | July 21, 2026 |
| Dauntless Investment Group, LLC13G, passive | 9.7% | March 3, 2025 |
| Bigger Michael13G, passive with 6 related filers | 6.1% | January 8, 2025 |
| Robert J Palmisano13D, may seek influence with 1 related filers | 5.7% | March 7, 2025 |
Largest institutional holders
Insiders
11 insiders reported holding 18,538,252 shares in total, about $3.3M at the last price.
| Holder | Shares |
|---|---|
| Lynch Timothy P10% owner | 6,500,000 |
| Bancroft Robert E.PRESIDENT & CEO, Director | 3,177,103 |
| Oh ChadCHIEF MEDICAL OFFICER | 2,183,436 |
| Wilson Alexander BlairCLO, CSO, and Corp Secretary | 2,183,005 |
| Sy JenniferPRINCIPAL ACCOUNTING OFFICER | 1,501,176 |
| Forth MarcDirector | 973,231 |
| Bencich JohnCHIEF FINANCIAL OFFICER | 754,717 |
| Fischer JostDirector | 489,469 |
| Palmisano Robert JDirector | 258,705 |
| Carter Eric GDirector | 258,705 |
Questions about AEON
What does AEON Biopharma, Inc. do?
AEON Biopharma, Inc. is a company in the Health care sector, listed on NYSE as AEON. Its shares trade on NYSE under the ticker AEON.
What is AEON Biopharma, Inc.'s net worth?
AEON Biopharma, Inc. has a market value (market cap) of $8.8M at the latest share price, and shareholders' equity of -$15.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AEON Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $54.6M.
When did AEON Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 30, 2026.
When is AEON Biopharma, Inc.'s next earnings report?
AEON Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AEON with
Follow AEON
Get an email when AEON Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AEON Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.